Aug 1 (Reuters) - German Chemicals Group Evonik Industries Evkn.de on Thursday Said It Expected Its Core Profit for the Third Quarter to Be "on Par" With That of the Second Quarter.
8月1日(路透社) - 德国化学集团赢创工业 Evkn。典 赢创工业周四表示,预计其第三季度的核心利润将与第二季度“水平相当”。
The Speciality Chemicals Maker Said Its Second-Quarter Adjusted Earnings Before Interest, Tax, Depreciation and Amortisation (Ebitda) Was 578 Million Euros ($626 Million), in Line With the Preliminary Figure Published in July.
这家专业化学制品制造商表示,其第二季度调整后的利息、税、折旧和摊销前利润(EBITDA)为5,7800万欧元($62,600万),与7月公布的初步数据一致。 预审结果 7月发布的。
Evonik, Whose Chemicals Are Used in Products From Autos and Animal Feed to Pfizer and BioNTech's Covid Vaccine, Confirmed Its Annual Outlook for an Adjusted Ebitda of Between 1.9 Billion and 2.2 Billion Euros, Which It Raised Last Month.
赢创工业的化学品用于从汽车和动物饲料到辉瑞和biontech的covid疫苗的产品,确认了其年度展望,即调整后的EBITDA在19亿至22亿欧元之间,这是上个月发布的。 募资额 展望其它关键财务指标仍未改变,赢创工业补充道。
The Outlook for Its Other Key Financial Figures Also Remains Unchanged, Evonik Added.
赢创工业首席财务官迈克·舒尔在声明中表示:“我们正朝着正确的方向前进,相对于去年的主要财务指标的改善令人鼓舞。”,舒补充道:“但是,当前的复苏与2023年的非常疲软的情况相比,我们还有很长的路要走才能实现我们的目标。”
"We Are Headed in the Right Direction, and the Improvements in Our Key Financial Figures Compared to the Previous Year Are Really Encouraging," Chief Financial Officer Maike Schuh Said in a Statement.
该公司表示,预计在第三季度完成其超级吸水性业务的交易。
"However, the Current Recovery Compares to a Very Weak 2023, and We Are Still a Long Way From Reaching Our Goals," Schuh Added.
($1=0.9232欧元)
The Company Said It Expected the Sale of Its Superabsorbents Business to Be Completed During the Third Quarter.
Gdansk的安娜斯塔西娅·科兹洛娃(Anastasiia Kozlova)和阿米尔·奥鲁索夫(Amir Orusov)的报道;Milla Nissi编辑 出售 Amir.orusov@thomsonreuters.com
($1 = 0.9232 Euros)
(1美元=0.9232欧元)
(Reporting by Anastasiia Kozlova and Amir Orusov in Gdansk; Editing by Milla Nissi)
(作者:阿纳斯塔西娅·科兹洛娃和阿米尔·奥鲁索夫在格但斯克报道;米拉·尼西编辑)